Excitation/Inhibition Modulators in Autism Spectrum Disorder: Current Clinical Research.
autism spectrum disorders
children and adolescents
excitation/inhibition imbalance
excitation/inhibition modulators
experimental treatments
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
08
2021
accepted:
08
11
2021
entrez:
17
12
2021
pubmed:
18
12
2021
medline:
18
12
2021
Statut:
epublish
Résumé
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by social and communication abnormalities. Heterogeneity in the expression and severity of the core and associated symptoms poses difficulties in classification and the overall clinical approach. Synaptic abnormalities have been observed in preclinical ASD models. They are thought to play a major role in clinical functional abnormalities and might be modified by targeted interventions. An imbalance in excitatory to inhibitory neurotransmission (E/I imbalance), through altered glutamatergic and GABAergic neurotransmission, respectively, is thought to be implicated in the pathogenesis of ASD. Glutamatergic and GABAergic agents have been tested in clinical trials with encouraging results as to efficacy and tolerability. Further studies are needed to confirm the role of E/I modulators in the treatment of ASD and on the safety and efficacy of the current agents.
Identifiants
pubmed: 34916897
doi: 10.3389/fnins.2021.753274
pmc: PMC8669810
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
753274Informations de copyright
Copyright © 2021 Canitano and Palumbi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Neurochem. 2010 Sep 1;114(5):1414-23
pubmed: 20557420
BMC Psychiatry. 2013 Jul 25;13:196
pubmed: 23886027
Autism Res. 2018 Jan;11(1):37-43
pubmed: 29045040
Curr Opin Genet Dev. 2013 Jun;23(3):310-5
pubmed: 23537858
Pediatrics. 2015 Aug;136(2):e539-43
pubmed: 26216321
PLoS One. 2012;7(5):e36981
pubmed: 22615862
Appl Psychophysiol Biofeedback. 2021 Jun;46(2):161-173
pubmed: 33877491
Epilepsy Behav. 2010 Apr;17(4):489-96
pubmed: 20236870
Neurosci Biobehav Rev. 2015 Aug;55:294-321
pubmed: 25957927
Neuron. 2015 Aug 19;87(4):684-98
pubmed: 26291155
Int J Neuropsychopharmacol. 2013 May;16(4):783-9
pubmed: 22999292
Autism Res. 2016 Feb;9(2):184-203
pubmed: 26536383
J Autism Dev Disord. 2000 Jun;30(3):205-23
pubmed: 11055457
Transl Psychiatry. 2012 Dec 11;2:e202
pubmed: 23233021
Clin Psychopharmacol Neurosci. 2020 Nov 30;18(4):527-552
pubmed: 33124586
World J Biol Psychiatry. 2016 Apr;17(3):174-86
pubmed: 26469219
Clin Neuropharmacol. 2015 Jan-Feb;38(1):11-7
pubmed: 25580916
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:701-721
pubmed: 32997602
Nat Rev Neurol. 2021 Sep;17(9):564-579
pubmed: 34341569
CNS Drugs. 2018 Aug;32(8):713-734
pubmed: 30105528
Curr Mol Med. 2015;15(2):146-67
pubmed: 25732149
J Child Neurol. 2007 May;22(5):574-9
pubmed: 17690064
Acta Paediatr. 2010 Dec;99(12):1885-8
pubmed: 20608900
Trends Neurosci. 2017 Sep;40(9):536-554
pubmed: 28818303
Pharmacol Res. 2019 Jan;139:207-214
pubmed: 30465851
Mol Autism. 2013 May 15;4(1):12
pubmed: 23675638
Biol Psychiatry. 2017 May 15;81(10):838-847
pubmed: 27450033
Sci Rep. 2020 Jun 8;10(1):9195
pubmed: 32513931
Psychiatry Res Neuroimaging. 2021 Jul 30;313:111302
pubmed: 34030047
Trends Pharmacol Sci. 2012 Dec;33(12):669-84
pubmed: 23084458
Expert Opin Pharmacother. 2016;17(7):937-52
pubmed: 26891879
Aust N Z J Psychiatry. 2017 Mar;51(3):241-249
pubmed: 27316706
Pharmacol Biochem Behav. 2012 Feb;100(4):850-4
pubmed: 21315104
J Child Adolesc Psychopharmacol. 2006 Oct;16(5):517-24
pubmed: 17069541
Mol Autism. 2016 Apr 21;7:26
pubmed: 27103982
Biol Psychiatry. 2012 Jun 1;71(11):956-61
pubmed: 22342106
J Child Adolesc Psychopharmacol. 2015 May;25(4):314-22
pubmed: 25919578
J Autism Dev Disord. 2014 Apr;44(4):958-64
pubmed: 24272415
Brain Res. 2016 Oct 1;1648(Pt A):277-289
pubmed: 27421181
Neuroimage Clin. 2013 Jul 02;3:65-72
pubmed: 24179850
Transl Psychiatry. 2017 Mar 14;7(3):e1056
pubmed: 28291262
Transl Psychiatry. 2021 Jan 21;11(1):71
pubmed: 33479207
Neuron. 2019 Feb 20;101(4):543-545
pubmed: 30790531
Neuropeptides. 2018 Dec;72:1-11
pubmed: 30287150
MMWR Surveill Summ. 2018 Apr 27;67(6):1-23
pubmed: 29701730
Neuropsychopharmacology. 2017 Jun;42(7):1390-1398
pubmed: 27748740
J Child Adolesc Psychopharmacol. 2015 Sep;25(7):585-8
pubmed: 26258842
Front Pediatr. 2014 Jul 08;2:70
pubmed: 25072038
Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):279-292
pubmed: 27766914
Psychopharmacology (Berl). 2007 Mar;191(1):141-7
pubmed: 17016714
Front Integr Neurosci. 2018 Jul 09;12:27
pubmed: 30038561
Mol Autism. 2020 May 11;11(1):32
pubmed: 32393347
J Child Adolesc Psychopharmacol. 2017 Jun;27(5):403-412
pubmed: 26978327
Nature. 2010 Nov 11;468(7321):263-9
pubmed: 21068835
J Autism Dev Disord. 2016 Mar;46(3):825-39
pubmed: 26443675
Metab Brain Dis. 2018 Jun;33(3):843-854
pubmed: 29397522
J Autism Dev Disord. 2018 Jul;48(7):2490-2505
pubmed: 29468576
Autism. 2015 Feb;19(2):149-57
pubmed: 24343334
Behav Brain Res. 2020 Jun 18;388:112603
pubmed: 32222380
Front Hum Neurosci. 2013 Sep 27;7:609
pubmed: 24098278
Curr Neurol Neurosci Rep. 2015 Jun;15(6):36
pubmed: 25946996
Br J Radiol. 2019 Sep;92(1101):20180944
pubmed: 31124710
Neuron. 2018 Oct 24;100(2):406-423
pubmed: 30359605
Neuroimage. 2014 Feb 1;86:1-9
pubmed: 23707581
Front Cell Neurosci. 2014 Dec 08;8:414
pubmed: 25538564
Autism Res. 2017 Apr;10(4):593-607
pubmed: 27696740
Curr Neuropharmacol. 2014 Jan;12(1):71-98
pubmed: 24533017
Nat Rev Drug Discov. 2006 Feb;5(2):160-70
pubmed: 16424917
Genes Brain Behav. 2003 Oct;2(5):255-67
pubmed: 14606691